A first one. Safety f[˘¯22or] these hig[˘¯22or]her dose. A sys. . .tematic. Regi[˘¯22or]mens are needed. A r[˘¯22or]eview. A systematic. A [˘¯22ormeta-analysis and doses of ivermectin was conducted] more. Eligible [˘¯22..reported patient-level] data and, for the meta-analysis, [˘¯22nical trials on doses ≥200 and ≥400 μg/kg were included]. Incidence ratios. Were u...56...sed to compare. Adverse events by severy and organ system affected. The [search identified six studies] for [inclusion]. Re[˘¯22..aling no differences in the number of individuals] experienci. . . ng adverse events. A descriptive [˘¯22sis] of these clinical trials for a variety of indications showed no [˘¯22.. of the adverse events] between. Standard and of ivermectin. Incidence [˘¯22.. to compare] adverse events. By [severy] and organ system affected. The [˘¯22..systematic search identified six studies] for inclusion, re[˘¯22..vealing no differences in the number of individuals] experiencing adverse events. A [on˘¯22]e more. A last one to check.
